524 related articles for article (PubMed ID: 34746195)
1. Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies.
Qu W; Ma T; Cai J; Zhang X; Zhang P; She Z; Wan F; Li H
Front Med (Lausanne); 2021; 8():761538. PubMed ID: 34746195
[TBL] [Abstract][Full Text] [Related]
2. Excess Body Weight and Metabolic (Dysfunction)-Associated Fatty Liver Disease (MAFLD).
Roeb E
Visc Med; 2021 Aug; 37(4):273-280. PubMed ID: 34540943
[TBL] [Abstract][Full Text] [Related]
3. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD.
Yamamura S; Eslam M; Kawaguchi T; Tsutsumi T; Nakano D; Yoshinaga S; Takahashi H; Anzai K; George J; Torimura T
Liver Int; 2020 Dec; 40(12):3018-3030. PubMed ID: 32997882
[TBL] [Abstract][Full Text] [Related]
4. Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy?
Kjær MB; George J; Kazankov K; Grønbæk H
Expert Rev Gastroenterol Hepatol; 2021 Jan; 15(1):51-64. PubMed ID: 32878486
[TBL] [Abstract][Full Text] [Related]
5. Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies.
Habibullah M; Jemmieh K; Ouda A; Haider MZ; Malki MI; Elzouki AN
Front Med (Lausanne); 2024; 11():1291501. PubMed ID: 38323033
[TBL] [Abstract][Full Text] [Related]
6. Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention.
Tacke F; Weiskirchen R
Ann Transl Med; 2021 Apr; 9(8):729. PubMed ID: 33987427
[TBL] [Abstract][Full Text] [Related]
7. MAFLD: Renovation of clinical practice and disease awareness of fatty liver.
Kawaguchi T; Tsutsumi T; Nakano D; Torimura T
Hepatol Res; 2022 May; 52(5):422-432. PubMed ID: 34472683
[TBL] [Abstract][Full Text] [Related]
8. Open Issues in the Transition from NAFLD to MAFLD: The Experience of the Plinio Study.
Baratta F; Ferro D; Pastori D; Colantoni A; Cocomello N; Coronati M; Angelico F; Del Ben M
Int J Environ Res Public Health; 2021 Aug; 18(17):. PubMed ID: 34501590
[TBL] [Abstract][Full Text] [Related]
9. Metabolic dysfunction-associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment.
Sangro P; de la Torre Aláez M; Sangro B; D'Avola D
J Physiol Biochem; 2023 Nov; 79(4):869-879. PubMed ID: 36976456
[TBL] [Abstract][Full Text] [Related]
10. MAFLD Criteria May Overlook a Subtype of Patient with Steatohepatitis and Significant Fibrosis.
Huang J; Xue W; Wang M; Wu Y; Singh M; Zhu Y; Kumar R; Lin S
Diabetes Metab Syndr Obes; 2021; 14():3417-3425. PubMed ID: 34349535
[TBL] [Abstract][Full Text] [Related]
11. Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?
Guerreiro GTS; Longo L; Fonseca MA; de Souza VEG; Álvares-da-Silva MR
Hepatol Int; 2021 Apr; 15(2):380-391. PubMed ID: 33694066
[TBL] [Abstract][Full Text] [Related]
12. Metabolic-associated fatty liver disease (MAFLD) in coeliac disease.
Rispo A; Imperatore N; Guarino M; Tortora R; Alisi A; Cossiga V; Testa A; Ricciolino S; Fiorentino A; Morisco F
Liver Int; 2021 Apr; 41(4):788-798. PubMed ID: 33319459
[TBL] [Abstract][Full Text] [Related]
13. Fibrosis Burden of Missed and Added Populations According to the New Definition of Metabolic Dysfunction-Associated Fatty Liver.
Park H; Yoon EL; Kim M; Kim JH; Cho S; Jun DW; Nah EH
J Clin Med; 2021 Oct; 10(19):. PubMed ID: 34640643
[TBL] [Abstract][Full Text] [Related]
14. The role of protein kinases as key drivers of metabolic dysfunction-associated fatty liver disease progression: New insights and future directions.
Alshehade S; Alshawsh MA; Murugaiyah V; Asif M; Alshehade O; Almoustafa H; Al Zarzour RH
Life Sci; 2022 Sep; 305():120732. PubMed ID: 35760093
[TBL] [Abstract][Full Text] [Related]
15. Comparison of MAFLD and NAFLD diagnostic criteria in real world.
Lin S; Huang J; Wang M; Kumar R; Liu Y; Liu S; Wu Y; Wang X; Zhu Y
Liver Int; 2020 Sep; 40(9):2082-2089. PubMed ID: 32478487
[TBL] [Abstract][Full Text] [Related]
16. Inflammation and Fibrogenesis in MAFLD: Role of the Hepatic Immune System.
Torre P; Motta BM; Sciorio R; Masarone M; Persico M
Front Med (Lausanne); 2021; 8():781567. PubMed ID: 34957156
[TBL] [Abstract][Full Text] [Related]
17. Association of Serum Vitamin C With NAFLD and MAFLD Among Adults in the United States.
Xie ZQ; Li HX; Tan WL; Yang L; Ma XW; Li WX; Wang QB; Shang CZ; Chen YJ
Front Nutr; 2021; 8():795391. PubMed ID: 35187020
[TBL] [Abstract][Full Text] [Related]
18. Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease.
Huang SC; Su HJ; Kao JH; Tseng TC; Yang HC; Su TH; Chen PJ; Liu CJ
Gut Liver; 2021 May; 15(3):451-458. PubMed ID: 33431715
[TBL] [Abstract][Full Text] [Related]
19. Liver fibrosis and MAFLD: the exploration of multi-drug combination therapy strategies.
Dong Q; Bao H; Wang J; Shi W; Zou X; Sheng J; Gao J; Guan C; Xia H; Li J; Kang P; Xu Y; Cui Y; Zhong X
Front Med (Lausanne); 2023; 10():1120621. PubMed ID: 37153080
[TBL] [Abstract][Full Text] [Related]
20. Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study.
Lee H; Lee YH; Kim SU; Kim HC
Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2138-2147.e10. PubMed ID: 33348045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
